24/7 Market News Snapshot 14 February, 2025 – OS Therapies Incorporated (NYSE:OSTX)

February 14, 2025

DENVER, Colo., 14 February, 2025 (247marketnews.com) – (NYSE:OSTX) are discussed in this article.
OS Therapies Incorporated (OSTX) has experienced a remarkable surge in its stock price, climbing 54.02% to $3.065 during pre-market trading, a significant increase from the previous closing price of $1.990. The robust trading activity, with 2.64 million shares changing hands, reflects a heightened interest among investors. This positive momentum is coupled with strong technical indicators suggesting the potential for continued upward movement in the stock, making it a focal point for both traders and long-term investors.

Parallel to this market enthusiasm, OS Therapies has made significant strides in the commercialization of its lead asset, OST-HER2, a pioneering immunotherapy targeting cancer. The company has secured agreements for the commercial production of OST-HER2 in anticipation of an important meeting with the U.S. Food & Drug Administration (FDA). This meeting will address data from a Phase 2b trial focused on preventing the recurrence of lung metastatic osteosarcoma, following a successful treatment phase.

With plans to submit a Biologics Licensing Application (BLA) for OST-HER2 by 2025, OS Therapies is strategically positioning itself for potential accelerated or conditional approval from the FDA. The company is hopeful of receiving a Priority Review Voucher upon approval, which could provide additional funding for its innovative programs.

OST-HER2’s unique approach harnesses the immune-stimulatory properties of Listeria bacteria to activate an aggressive immune response against the HER2 protein. It has been recognized by the FDA as a rare pediatric disease, receiving fast-track status and orphan drug designation, highlighting its transformative potential for treating osteosarcoma and other solid tumors. Furthermore, OS Therapies is progressing its next-generation Antibody Drug Conjugate (ADC) platform, utilizing cutting-edge silicone linker technology for tailored cancer treatment delivery, further underscoring its commitment to advancing oncology options for improved patient outcomes.

Related news for (OSTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.